This Biopharma Stock Hit a 6-Year High-and It Can Keep Climbing -- Barrons.com

By Mariapaula Gonzalez

Neurocrine Biosciences stock was on a tear Tuesday, and its flagship movement-disorder drug wasn't the only engine driving the rally.

After the market close on Monday, Neurocrine Biosciences reported strong third-quarter earnings. Adjusted earnings per share of $3.29 comfortably topped analysts' consensus estimate of $2.61. Revenue totaled $1.12 billion in the third quarter, topping Wall Street's estimated of $1.04 billion.

Shares of the biotech company jumped 15% to $166.55, heading for their best single-day percentage gain since Nov. 4, 2020, according to Dow Jones Market Data. The stock has risen about 15% this year, including Tuesday's action.

Third-quarter revenue for Neurocrine's flagship treatment, Ingrezza, climbed to $801 million during the third quarter, up from analysts' consensus target of $737 million. The once-daily oral pill treats adults with tardive dyskinesia, a condition characterized by uncontrollable body movements, as well as people experiencing chorea, or the jerky, dance-like involuntary movements associated with Huntington's disease.

Not only were Ingrezza's third-quarter numbers good, but Neurocrine projects continued growth through the end of the year. Management lifted guidance for the drug's 2026 revenue, saying it now expects a range of $2.9 to $2.925 billion, up from a prior outlook of $2.825 billion to $2.875 billion.

Ingrezza didn't hog the spotlight, either. Revenue for Crenessity totaled $211 million, beating Wall Street's calls for $203 million. The drug, which received approval from the Food and Drug Administration in late 2024 to treat classic congenital adrenal hyperplasia, helps reduce excess androgens and patient dependence on high-dose steroid therapy.

Oppenheimer analyst Jay Olson called Crenessity's performance "encouraging," noting that the numbers point to accelerating market penetration. The firm carries an Outperform rating on the stock with a $230 price target.

Truist Securities analysts echoed Olson's sentiments. They pointed out that Crenessity has plenty of runway ahead, estimating that only about 15% of the target patient population has been treated so far. Truist reiterated its Buy rating and $213 price target.

Of the 31 analysts polled by FactSet, 27 recommend buying Neurocrine Biosciences stock. Only four have a Hold rating on shares.

Meanwhile, newly integrated Vykat XR, which treats hyperphagia in Prader Willi syndrome, brought in $107 million in revenue, topping consensus estimates of $98 million. Neurocrine added the drug to its offerings through its acquisition of Soleno Therapeutics in May. Wedbush analyst Laura Chico noted that, while eight patient deaths have surfaced in the FDA's adverse-event database, management remains confident in the drug's safety. The firm has an Outperform rating on Neurocrine with a $186 price target.

Barron's named Neurocrine Biosciences a stock pick on Oct. 13. Shares have risen 7.6% since then through the close of trading Monday, according to Dow Jones Market Data.

Write to Mariapaula Gonzalez at mariapaula.gonzalez@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

November 03, 2026 13:03 ET (18:03 GMT)